KADONO, Yoshifumi et al. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urology Journal, [S. l.], v. 19, n. 03, p. 202–208, 2021. DOI: 10.22037/uj.v19i03.6652. Disponível em: https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/6652. Acesso em: 8 jul. 2026.